Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions
Boric acid, Placebo
Drug · Other
Lead sponsor
pH-D Feminine Health LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more
Conditions
Breast Adenocarcinoma
Interventions
Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4,994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
840
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Terminated Phase 2 Interventional Results available

Sodium Nitroprusside in Early Course Schizophrenia

NCT04986072
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sodium Nitroprusside, 5% Dextrose solution
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Aerosol in a Dental Clinic

NCT04659928
Conditions
Covid19
Interventions
High volume evacuation (HVE), Extraoral vacuum aspirator (EVA), Hydrogen Peroxide, Placebo
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT05954286
Conditions
SARS-CoV-2
Interventions
Upamostat, Placebo (PO)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Conditions
Pain, Cancer, Colonic Diseases
Interventions
GIC-1001
Drug
Lead sponsor
gicare Pharma Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Anaheim, California • Chula Vista, California + 8 more
Conditions
Chronic Fatigue Syndrome (CFS)
Interventions
Placebo condition, Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.
Dietary Supplement
Lead sponsor
Fred Friedberg
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions
Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O)
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Capecitabine, Laboratory Biomarker Analysis, Placebo
Drug · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
45
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mouth Rinses for Inactivation of COVID-19

NCT04584684
Conditions
Covid19, Coronavirus Infection, SARS-CoV-2 Infection
Interventions
0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide, 0.075% Cetylpyridinium Chloride
Other · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure

NCT00804999
Conditions
Normal Contact Lens Wear
Interventions
Clear Care, ReNu, OPTI-FREE
Drug
Lead sponsor
Christine Sindt
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Parkinson Disease
Interventions
Hydrogen, Placebo oral tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
40 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Malignant Glioma
Interventions
Hydrogen, Placebo oral tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Targeting ER Stress in Vascular Dysfunction

NCT04001647
Conditions
Vasodilation, Arterial Stiffness
Interventions
Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Determining Lipid Content in Stool After Alpha-cyclodextrin

NCT03002168
Conditions
Healthy Participants
Interventions
Alpha-cyclodextrin, Placebo, Triolein radiolabeled with 100 microcuries of 3^Hydrogen, Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Dietary Supplement · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Durvalumab, Nintedanib, Placebo, Quality-of-Life Assessment
Biological · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Biocidin REMOVE, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland